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Abstract 
Hepatocellular adenomas are benign tumors that can be difficult to diagnose. To refine their 
classification, we performed a comprehensive analysis of their genetic, pathological and clinical 
features. A multicentric series of 96 liver tumors with a firm or possible diagnosis of 
hepatocellular adenoma was reviewed by liver pathologists. In all cases, the genes coding for 
hepatocyte nuclear factor 1 (HNF1) and ß-catenin were sequenced. No tumors were mutated 
in both HNF1 and ß-catenin enabling tumors to be classified into 3 groups, according to 
genotype. Tumors with HNF1 mutations formed the most important group of adenomas (44 
cases). They were phenotypically characterized by marked steatosis (p<10
-4
), lack of cytological 
abnormalities (p<10
-6
) and inflammatory infiltrates (p<10
-4
). In contrast, the group of tumors 
defined by ß-catenin activation included 13 lesions with frequent cytological abnormalities and 
pseudo-glandular formation (p<10
-5
). The third group of tumors without mutation, was divided in 
two subgroups based on the presence of inflamatory infiltrates. The subgroup of tumors 
consisting in 17 inflammatory lesions, resembled telangiectatic focal nodular hyperplasias, with 
frequent cytological abnormalities (p=10
-3
), ductular reaction (p<10
-2
) and dystrophic vessels 
(p=0.02). In this classification, hepatocellular carcinoma associated with adenoma or borderline 
lesions between carcinoma and adenoma is found in 46% of the ß-catenin mutated tumors 
whereas they are never observed in inflammatory lesions and are rarely found in HNF1 mutated 
tumors (p=0.004). The molecular and pathological classification of hepatocellular adenomas 
permits the identification of strong genotype-phenotype correlations and suggests that adenomas 
with ß-catenin activation have a higher risk of malignant transformation. 
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Introduction 
Hepatocellular adenomas (HA) are rare benign liver tumors, most frequently occurring in women 
using oral contraception(1). HA are single or more rarely multiple nodules; the presence of more 
than ten nodules in the liver indicates a specific nosological entity: liver adenomatosis(2). In 
1978, Foster and collaborators described another clinical entity, which was the first case of 
familial adenomatosis associated with diabetes(3), later confirmed by others(4-7). Some small 
HA may regress after withdrawal of oral contraceptives; however, they usually remain stable, or 
increase in size. They may bleed, or rarely, undergo malignant transformation(8, 9). Given the 
unpredictable evolution of these lesions, they are generally surgically removed. Moreover, it may 
be difficult for pathologists to differentiate HA from well-differentiated hepatocellular carcinoma 
(HCC), or sometimes from regenerative lesions such as focal nodular hyperplasia (FNH) and 
particularly from telangiectatic focal nodular hyperplasia(10) (TFNH), recently identified as 
monoclonal lesions(11, 12) subject to frequent bleeding(11, 12).  
Recently, genetic alterations have been identified in HA. Mutations of the TCF1 gene 
inactivating the Hepatocyte Nuclear Factor 1 (HNF1) transcription factor, were identified in 
half of the HA cases(5) and most frequently both allelic mutations were somatic. Patients with an 
inherited mutation in one allele of HNF1 may develop maturity onset diabetes of the young type 
3(13) (MODY3, OMIM#600496) and familial liver adenomatosis, when the second allele is 
inactivated in hepatocytes by somatic mutation or chromosome deletion(5-7) (OMIM#142330). 
These results showed that the HNF1 transcription factor gene fulfils the genetic characteristics 
of a tumor suppressor gene and is a factor for genetic predisposition to familial hepatocellular 
tumors(14). Furthermore, HNF1 mutations occur specifically in adenomas among the benign 
hepatocellular tumors since no mutations were identified either in typical FNH or TFNH 
5 
cases(11, 12), in contrast to rare mutations observed in endometrial, colon and renal 
carcinomas(15-17). Recently, activation of the ß-catenin pathway was also found in HA(18-20). 
On the other hand, activating mutations of ß-catenin are found in 20 to 34% of hepatocellular 
carcinomas(21-24) suggesting that ß-catenin is the most frequently activated oncogene in HCC. 
Furthermore, this pathway plays a key role in liver physiological phenomena, such as lineage 
specification, differentiation, stem cell renewal, epithelial-mesenchymal transition, proliferation 
and cell adhesion(25, 26). 
The aim of the present study was to characterize HNF1 and ß-catenin mutations in a large series 
of HA and to relate the molecular findings to the histopathology, in order to clarify the 
classification of these tumors into homogeneous subgroups that might have different evolutive 
potential, especially with regard to malignant transformation. 
6 
Patients and methods 
1 Liver samples and clinical data 
A group of 13 French university hospitals has participated in this retrospective study and 96 
patients were recruited between 1992 and 2004. Criteria of inclusion in the study were a definite 
(87 cases) or possible (9 cases) diagnosis of adenoma and an adequate sampling of frozen and 
fixed liver tissues following hepatectomy (95 cases) or transplantation (1 case). No case 
previously diagnosed as typical FNH or typical HCC, without associated adenoma, were included 
in this study. Among the 96 included cases, 18 were previously described(5, 7). For each case, a 
representative part of the principal nodule, as well as of the non tumoral liver, was immediately 
frozen in liquid nitrogen and stored at – 80C° until used for molecular studies. When multiple 
nodules were present, one representative lesion was selected and the same lesion was analyzed by 
molecular biology and reviewed morphologically. This pathological/genotypic correlation was 
limited, for technical reasons, to an area of the nodule which was not necrotic or hemorrhagic. In 
the vast majority of the cases, lesions were macroscopically homogeneous; in five cases in which 
adenoma and HCC coexist, HCC lesions were also genetically and morphologically analyzed but 
only adenomas lesions were included in the statistical analysis. Clinical data for oral 
contraception, individual and familial history, circumstances of diagnosis and the associated 
diseases were systematically collected. All patients were recruited in accordance with French law 
and institutional ethical guidelines. The overall design of the study was approved by the ethical 
committee of hospital Saint-Louis, Paris France. 
2 Pathological reviewing 
Paraffin tissue sections were stained with hematein-eosin, as well as in most of the cases, with 
Masson’s trichrome, reticulin and Perls. Additional immunostaining were also performed in some 
7 
cases with cytokeratins 7 and 19,  smooth muscle actin, and CD34, in order to better visualize, 
if necessary, biliary structures, arteries and capillarisation of sinusoids, respectively. A group of 
10 liver pathologists (PBS, MF, ESZ, CG, VP, JTVN, J-YS, EL, SM and DW) reanalyzed all 
cases in 4 collective reviewing sessions and among them, 5 pathologists participated in all 
sessions to ensure uniform evaluation. For each case a set of 20 variables were systematically 
recorded, including the macroscopic characteristics of the tumors (size, number, presence of 
hemorrhage, necrosis), and microscopic features such as the presence of a fibrous capsule, sharp 
outlines, sinusoidal dilatation, dystrophic vessels included in a connective tissue matrix, multiple 
vessels (dispersed in the tumor and visible at x 4 magnification), presence of fibrous bands, 
steatosis (graded as mentioned below), and ductular reaction. In addition, inflammatory infiltrate 
(either focal or diffuse, visible at 10X magnification) as well as cytological abnormalities (large 
and irregular nuclei, high nucleo/cytoplasmic ratio, Mallory bodies) and pseudo-glandular 
formations were also noted. The non-tumor tissue was evaluated for fibrosis, according to the 
METAVIR score(27), for sinusoidal dilatation and for peliosis. In both tumor and non-tumor 
tissues, steatosis was evaluated as either absent, or involving less than 1/3 of the hepatocytes, or 
of 1/3 to 2/3 of the hepatocytes, or of more than 2/3 of the hepatocytes. At the end of every case 
review, each pathologist made a diagnosis, which was considered definitive if at least 80% of the 
pathologists agreed and 87% of the initial diagnoses were confirmed by these reviews. The 
pathological diagnosis of adenoma, HCC, TFNH and FNH was made according to classical 
criteria(28). 
Briefly, typical adenoma corresponded to a proliferation of benign hepatocytes, intermingled with 
numerous thin-walled vessels, without portal tracts. In typical, solid FNH, pseudo-cirrhotic 
nodules made of (sub)normal hepatocytes were separated by more or less thick fibrous bands, 
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mixed with malformed vascular, especially arterial structures, inflammatory cells mainly 
lymphocytes, and ductular reaction. TFNH corresponded to hepatocellular proliferation without 
nodular organization but with portal tract-like structures containing thick arterial sections, mixed 
with inflammatory cells and a more or less obvious ductular reaction. Finally, the diagnosis of 
well-differentiated HCC was made in case of architectural abnormalities (such as arrangement in 
more than 3 cell-thick plates, numerous acinar structures), often associated with cytological 
anomalies. When a clear differential diagnosis was not possible, lesions were considered 
borderline with two possible diagnoses.  
3- Mutation screening 
In all tumors, we sequenced the HNF1 and ß-catenin genes using direct sequencing of the exons 
after amplification of genomic DNA to identify mutations, as previously described(5, 24). In 
addition, to detect any large ß-catenin deletions we performed a PCR amplification using a 5’ 
located exon2 (GGGTATTTGAAGTATACCATAC) and a 3’ located exon 4 
(TGGTCCTCGTCATTTAGCAG) primers on DNA templates. In samples that showed over-
expression of the ß-catenin target genes (GLUL and GPR49) but without the exon3 ß-catenin 
activating mutation, we sequenced all of the Axin1 and ß-catenin coding exons using direct 
sequencing on DNA or RT-PCR amplified templates, respectively (all detailed primers and 
protocols are available upon request). All mutations were confirmed by sequencing DNA from 
two independent PCR amplifications of DNA from tumor and corresponding non-tumor tissues.  
4- Quantitative RT-PCR 
Activation of ß-catenin results in transcriptional activation of targeted genes and the 
overexpression of GS and GPR49, coding for glutamine synthetase and for an orphan nuclear 
receptor, respectively, are reliable markers of the ß-catenin activation in HCC (29, 30). In 68 
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tumors and 8 non-tumor tissues, the quality of RNA extracted using the RNeasy kit (Qiagen) 
enabled us to perform quantitative RT-PCR experiments as previously described(15). We used 
sequence detection reagents primers and probes specific for GS (glutamine synthetase), GPR49, 
18S (ribosomal RNA) developed by Applied Biosystems. The relative amount of mRNA in 
samples, was determined using the 2
-∆∆CT
 method(31). The values obtained were expressed as the 
n-fold ratio of the gene expression in a tested sample compared to the mean of non-tumor tissues. 
PCR efficiency was measured using LinRegPCR software(32). All gene assays demonstrated a 
PCR efficiency superior to 90%.  
5- Statistical analysis 
Statistical analysis was carried out using Stata 8.0 software (Stata Corp, College Station, TX). 
Qualitative and categorized quantitative variables were compared to each other in contingency 
tables using a chi-square statistic or Fisher’s exact test. For quantitative variables, data were 
expressed as mean and its standard error. The differences between quantitative variables were 
evaluated with a t-test or ANOVA when the variances were similar, or with the Kruskall-Wallis 
test when the data was heteroskedastic. All reported P values were two-tailed; a P value of less 
than 0.05 was considered to indicate statistical significance. 
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Results  
1- Clinical and pathological features of the patients. 
Among the 96 patients included in the series for a presumed diagnosis of HA, the sex ratio (F:M) 
was 8:1 and the mean age was 37 years (range 14-78). Among the 83 females, 72% had taken 
oral contraception for longer than 2 years (mean duration=12 years, excluding 9 cases with 
missing data). One case was diagnosed during pregnancy and 4 patients presented an associated 
endometriosis. The presenting symptoms were acute abdominal pain in 28% of the cases, 
abdominal pain of more than 1 month duration in 26% of the cases, and the remaining cases were 
discovered on routine check-up or investigation for unrelated disorders. We noted several 
associated rare pathologies in individual cases, including familial adenomatous polyposis, 
meningioma, Fanconi anemia (treated by androgen therapy), primary hyperoxaluria type 1, renal 
dysplasia, Crohn’s disease and a portal cavernoma treated by a mesenterico-caval anastomosis. 
Other associated diseases were: a polycystic kidney disease and a glycogen storage disease type 
Ia in 2 cases, respectively. Finally an HCV infection combined with alcohol abuse was observed 
in one case and three independent patients had first degree relatives with liver adenomatosis. 
Adenomatosis was defined by the presence of 10 or more adenoma nodules in the liver (18 
cases), whereas we classified as “multiple adenomas” 27 cases where 2 to 6 nodules were found 
(no patients presented 7 to 9 nodules) in the liver. 
The pathological reviewing led to a final diagnosis with a consensus of the committee in 77 
cases: 68 HA, 5 HA with areas of HCC, 3 TFNH and 1 HCC. The remaining 18 cases were 
classified as borderline: 6 HA/HCC, 6 HA/FNH, and 6 HA/TFNH. Finally, in one case no 
diagnosis was retained and remained unclassifiable. The corresponding non-tumor liver tissues 
was normal in 60 cases. In the remaining 36 cases the pathological analysis showed a F2 (2 
11 
cases) and F3 (2 cases) fibrosis, a moderate sinusoidal dilatation (5 cases), a steatosis (23 cases), 
an iron overload (2 cases) and polycystic lesions in 2 cases. 
2- Molecular analyses 
a- Mutation of HNF1 in adenomas and correlations with phenotype 
We identified HNF1 mutations in 44 of the 96 tumors screened (46%). In each case two HNF1 
mutations were identified in tumors. Both mutations were of somatic origin in 37 cases (84%), 
whereas in the remaining 7 patients one mutation was germline and the other was somatic (Figure 
1). Mutations were non-sense, frameshifts or splicing alterations in half of the cases (Figure 1 
upper panel), gene deletion (LOH) in 15% of the cases and amino-acid substitution in 35% of the 
cases (Figure 1 lower panel). All but 4 of the mutations leading to amino acid substitution were 
restricted to the POUH homeodomain and altered an amino-acid conserved through different 
species (Figure 1 and table 1). Two hotspots of mutations were found at codon 291 and 206. The 
codon 291 substitution located in a polyC-8 tract is the most frequent mutation found in MODY3 
patients, whereas the codon 206 mutation, which was not contained in a repeated sequence motif, 
was specific to adenomas(33). 
Lesions containing HNF1 mutations were mainly adenomas with a firm diagnosis (37 out of the 
44 cases; 84%). The other tumors were diagnosed as borderline lesion between adenoma and 
HCC (2 cases), or between adenoma and FNH (4 cases); in 1 additional case, part of the adenoma 
was associated with an HCC (Table 2). So mutations in this gene seem to lead the most usual 
form of adenoma. Analysis of the pathological and clinical data revealed that HNF1 mutations 
were observed in a homogeneous group of tumors closely associated with marked steatosis 
(p<10
-4
), and no cytological abnormalities (p=10
-5
, Table 2 and Figure 2) or inflammatory 
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infiltrate (p<10
-4
). Germline HNF1 mutations defined a specific subgroup of patients who were 
younger (mean age= 23 vs 40 years old; p=0.0001, T-test), with known familial liver 
adenomatosis in three of the cases (p=0.003 Fisher). Women with germline HNF1 mutations 
were less likely to have used oral contraception when compared to women presenting biallelic 
HNF1 somatic mutations (p=0.002, Fisher). Patients with germline mutations in HNF1 
developed larger tumors than patients with biallelic somatic mutations (mean size 142 mm vs 69 
mm, p= 0.02 Kruskall Wallis) and tumors were more numerous, with 4 patients presenting more 
than 10 nodules, larger than 1 cm (p=0.04, Fisher). Furthermore in 5 out of the 7 patients 
presenting germline mutation, numerous infracentimetric steatotic adenomas were detected in the 
liver at distance from the principal nodule. The other characteristics did not differ significantly in 
relation to the germline or somatic origin of the mutation.  
b- ß-catenin mutations and tumors over-expressing ß-catenin target genes and correlations 
with phenotype 
We found ß-catenin gene alterations in 12 cases (Table 3). In 6 of these cases we found a large 
deletion including the exon 3 and frequently most of exon 4. In five cases we found an amino-
acid substitution altering a site of phosphorylation by GSK3. In the last case, an amino-acid 
substitution was observed at lysine 335, an amino-acid which binds E-cadherin and TCF3 when 
phosphorylated(34). In ß-catenin mutated tumors, two ß-catenin target genes, GS and GPR49, 
were over-expressed 42-fold (ranging from 9 to 87) and 35-fold (ranging from 8 to 57) when 
compared with non-tumor tissues, respectively (Figure 3). All but one non-tumor tissues and non-
ß-catenin-mutated tumors demonstrated a GS and GPR49 expression ranging from 0.2 to 4 and 
from 0.01 to 4, respectively (Figure 3). In no tumor over-expression of only one of the two tested 
ß-catenin target genes was observed. In one additional adenoma (case 485), GS and GPR49 were 
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over expressed (39-fold and 48-fold, respectively), in the absence of detectable ß-catenin or axin1 
mutation. In the group of tumors where the ß-catenin pathway was activated, including the 12 
tumors mutated for ß-catenin and the case n° 485, 7 cases had a firm diagnosis of adenomas, 2 
were borderline lesions between adenomas and HCC, 3 were cases of adenoma associated with 
an HCC and 1 was a tumor reclassified as HCC (in a young male of 15 years old) (Table 2). Male 
patients were over-represented in this ß-catenin activated group (5 cases, 38% p=0.02), and of the 
8 females all but one female were using oral contraceptives. This group of 13 lesions presented 
specific characteristics when compared with non-ß-catenin activated tumors. ß-catenin activated 
tumors frequently showed cytological abnormalities and pseudo-glandular formation since they 
were observed in 69% of the cases, (p<0.002), whereas they were less frequently steatotic (p=10
-
4
, Fisher) and more frequently diagnosed as borderline lesions between adenoma and HCC or 
associated with HCC (p=10
-3
, Fisher, Table 2, Figure 2). 
c- Non-mutated adenomas and correlations with phenotype 
The first two categories shown above of tumors with mutation of HNF1 and activation of ß-
catenin account for 58% of the tumors. In the remaining 39 tumors not having a mutation in 
either of these genes, we found 17 cases with focal or diffuse inflammatory infiltrates; a much 
higher incidence than the two HNF1 mutated and three ß-catenin activated cases (Table 2). In 
this group with no mutations but showing inflammatory infiltrates, the tumors had significantly 
more ductular reaction (p=0.008), dystrophic vessels (p=0.02), numerous vessels (p=0.01) and 
cytological abnormalities (p=0.001) when compared to the whole series. All together, these 
inflammatory tumors resemble TFNH and accordingly, 3 diagnoses of firm TFNH and 5 
borderline lesions between adenoma and TFNH were classified in this group by expert 
pathologists. The remaining 22 tumors consisted of lesions without HNF1 mutation, ß-catenin 
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activation or inflammatory infiltrate. No specific clinical or morphological features were typical 
for this latter group.  
3- Classification of hepatocellular adenomas 
Our sequencing results revealed 3 groups of HA, according to the presence of either HNF1 or ß-
catenin mutations, or no mutations and in this last group, a fourth subset of tumors was defined 
by the presence of inflammatory infiltrates. Therefore, based on the three criteria, HNF1 
mutations, ß-catenin activation and the presence or the lack of inflammatory infiltrates, we 
identified 4 groups of hepatocellular adenomas. These three criteria enable us to unambiguously 
classify 91 out of the 96 tumors in the four groups of tumors (Figure 4). Only two lesions were 
simultaneously inflammatory and HNF1 mutated and three others were inflammatory and ß-
catenin mutated and hence difficult to classify precisely.  
In an alternative analysis we first took the major clinical and morphological criteria and searched 
for correlations with the above defined classification. Adenomatosis and multiple adenomas 
seemed more likely to have HNF1 mutations but the frequency was not significantly different 
from that of ß-catenin activation. Microscopic hemorrhages (55 cases) and clinical hemorrhagic 
syndrome (32 cases) were almost equally distributed among the different defined subgroups of 
tumors. Interestingly, in the group of HNF1 mutated tumors, there was no significant 
relationship between the size of the nodules and the presence of hemorrhages (mean 85 vs 77 
mm) in contrast to that observed in the non-HNF1 mutated tumors in which hemorrhages were 
significantly associated with higher diameter of the nodules (86 vs 53 mm, p<0.01, t-test). 
Interestingly the two cases associated with hepatic polycystic disease were HNF1 mutated 
whereas among the two cases of adenomatosis associated with glycogenosis type I, one was ß-
15 
catenin mutated, when the other was non-mutated and non-inflammatory. Apart from 
morphological characteristics used for diagnosis of malignant tumors, HCC and borderline 
lesions between adenomas and HCC were significantly associated with ß-catenin activation and 
the absence of inflammatory infiltrates in the lesion (p=0.004, Figure 4).  
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Discussion 
Our study demonstrates close genotype-phenotype correlations in hepatocellular adenomas. Our 
comprehensive analyses of a large series of tumors including molecular, clinical and 
morphological data revealed that HNF1 mutations and ß-catenin activation lead to different 
tumor subtypes with specific characteristics. HNF1 mutations result in adenomas that are 
noticeably steatotic, whereas ß-catenin activated lesions were frequently characterized by pseudo-
glandular formation and cytological abnormalities. Furthermore tumors that are not mutated in 
either gene but that have inflammatory infiltrates seem to define a third subgroup of tumors that 
we termed “inflammatory adenoma”. These lesions also had marked vessel dystrophy and 
resembled TFNH(10, 12). These results reveal a heterogeneity of HA and enable us to propose a 
new classification of these tumors, with some clinical implications.  
Since non-inflammatory and more specifically ß-catenin activated HA are most frequently 
associated with HCC or borderline tumors where the differential diagnosis between adenoma and 
HCC is difficult, we can hypothesize that these tumors have a higher risk of malignant 
transformation. Consequently, patients falling into this subgroup could be closely followed to 
detect any early recurrence. 
Mutations of HNF1 and activation of the ß-catenin pathway are found in benign hepatocellular 
tumors, suggesting these genes play a role at an early stage of hepatocellular tumorigenesis. In 
three patients, we identified the same nucleotide mutation of ß-catenin in the adenoma and in the 
HCC part of the tumors (data not shown) indicating that the benign and malignant lesions had the 
same clonal origin. Since HCC or borderline tumors are more frequently associated with ß-
catenin activation, alteration of this pathway may promote a faster malignant transformation than 
HNF1 inactivation. These results are corroborated by the high frequency of ß-catenin activating 
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mutations found in HCC (20 to 34% of the cases(21-24)) contrasting with the low frequency of 
HNF1 inactivation in HCC (3 mutated cases out of 120 screened HCC (5) and unpublished 
data). 
Inflammatory adenomas not carrying mutations in either of the above two genes shared 
morphological and genetic features with TFNH for which no HNF1 or ß-catenin mutation was 
observed(12). This result permits us to propose TFNH as part of a larger group of “inflammatory 
adenomas”. As with the ß-catenin mutated lesions, the inflammatory adenomas were frequently 
associated with cytological abnormalities, but considered more probably dystrophic than 
premalignant, since no cases of borderline lesions between adenoma and HCC or adenomas 
associated with HCC were observed in this inflammatory adenoma group. These results should 
be confirmed in a prospective study in order to translate them in clinical guidelines, since the 
diagnosis of liver adenoma remains a challenge even for liver pathologists. This is well illustrated 
in this retrospective study regarding the diagnosis of benign hepatocytic nodules proposed by 
each pathologist. Difficulties leading to the lack of diagnostic consensus were mainly for nodules 
looking-like adenomas but with some features of FNH classified as adenomas by some, and 
TFNH by others and for nodules with cytological abnormalities classified as adenomas with areas 
of HCC or borderline lesions. This genotype/phenotype correlations might facilitate classification 
of these “borderline” tumors. 
An accurate adenoma classification is also important to elucidate genetic predisposition to 
develop hepatocellular adenomas. We previously showed that germline HNF1 mutations 
predispose to liver adenomatosis and maturity onset diabetes type 3 (MODY3)(5-7). These 
observations suggested that relatives of patients presenting germline HNF1 mutation should be 
investigated for familial liver adenomatosis. Other genetic predispositions may be identified, 
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particularly to explain the occurrence of multiple adenomas in patients. We showed by 
genotyping different nodules in the same patients that multiple lesions may have different 
HNF1 mutations, indicating their independent origin but simultaneous development (data not 
shown). Furthermore, the incomplete penetrance of the adenomatosis phenotype in HNF1 
germline mutated patient may suggest the existence of modifier genes. Interestingly, our familial 
adenomatous polyposis patient associated with an APC germline gene mutation also showed 
HNF1 somatic mutations in its hepatocellular adenoma without loss of the second APC allele 
and without over-expression of ß-catenin targetted genes. This observation contrast with a 
previously reported cases of hepatocellular adenoma related to FAP and presenting a ß-catenin 
activation(35, 36). 
Finally, such classification will facilitate the search for specific alterations of carcinogenetic 
pathways by providing homogeneous subgroups of tumors for comparison or study. The 
molecular and pathological classification of hepatocellular adenomas permits the identification of 
strong genotype-phenotype correlations and suggests that adenomas with ß-catenin activation 
have a higher risk of malignant transformation. Furthermore, a genetic counselling should be 
recommended to patient with adenomatosis in particular when steatotic or with familial history to 
search for germline HNF1 mutation. 
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Table 1: HNF1 mutations identified 
N°ID  
Tumor Tissue 
 Non tumor tissue 
Allele 1 Allele 2 
340* 685C>T, R229X LOH R229X 
357* IVS2+1G>A 618G>T, W206C nm 
358* 617G>T, W206L 872_884del, P291fs nm 
368* 710A>G, N237S LOH nm 
369* 436_437delC, Q146fs LOH nm 
370* 872_873insC, P291fs 803T>G, F268C nm 
371* 617G>T, W206L 730A>G, R244G nm 
373* 82C>T, Q28X LOH nm 
380 196G>T, E66X 779C>T, T260M nm 
383 493T>A, W165R 1340C>T, P447L nm 
385 817A>G, K273E LOH nm 
461 872_873insC, P291fs 872_873delC, P291fs nm 
462 632A>C, Q211P 617G>T, W206L nm 
464 71_82del, A25_Q28del 747_764del, Q250_G255del nm 
474 617G>T, W206L LOH nm 
476 232_245dup, T81fs 1288_1289delG, G430fs nm 
479 476_479del, R159fs 811C>T, R271W nd 
482 653 A>G, Y218C LOH nd 
487 814 C>A, R272S LOH R272S 
489 IVS1-2 A>T 1072_1073delCins11, P358fs nd 
508 77T>A, L26Q 872_873delC, P291fs nm 
509 391C>T, R131W 872_873delC, P291fs P291fs 
514** 829_837del, F277_H279del 872_873insC, P291fs P291fs 
516 185_194del, N62fs 788G>A, R263H nm 
518# 164_168del, G55fs LOH G55fs 
523** 872_873insC, P291fs LOH P291fs 
532 198_202del, T67fs 618G>T, W206C nm 
535 617G>T, W206L 872_873insC, P291fs nm 
539 686G>A, R229Q 775G>C, V259L nm 
540 618G>T, W206C LOH nm 
546  1 A>G, M1X 620G>A, G207D nm 
575 IVS2+1 del13 956_957delG, G319fs nm 
583 811_818del, R271fs 815G>A, R272H nm 
584 607C>T, R203C  710A>G, N237S nm 
590 257_258del, L86fs IVS2+1 G>T IVS2 +1 G>T 
20 
591 787C>T, R263S LOH nm 
592 526C>T, Q176X IVS5-2 A>G, S371fs nm 
635 618G>C, W206C 872_873insC, P291fs nm 
682 197_198insA, T67fs 872_873insC, P291fs nm 
687 814C>A, R272S LOH nm 
694 682G>T, E228X  IVS2_2 A>G nm 
696 872_873insC, P291fs 1168G>T, E390X nm 
699 685C>G, R229G 710_711insA, N237fs nm 
705 618G>T, W206C 631C>T, Q211X nm 
fs: frameshift; ins:insertion; del:deletion; nm: non-mutated; previously described in *Bluteau et 
al.(5), in **Reznik et al.(7) and in #Bacq et al.(6)  
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Table 2: Main clinical and pathological characteristics according to the genotype classification 
 
HNF1 
mutated 
n=44 
ß-catenin 
activated 
n=13 
Non-
mutated 
n=39 
P value* 
Non mutated cases 
Inflamatory 
n=17 
Non-
inflamatory 
n=22 
Mean age ± SD (y) 37±12 32±16 39±12 ns 42±10 37±12 
Male 9% (4) 38% (5) 10% (4) 0.02 12% (2) 9% (2) 
Oral contraception  67% (24) 87% (7) 73% (22) ns 92% (11) 61% (11) 
Acute Symptoms at 
diagnosis 
25% (10) 25% (3) 35% (12) ns 29% (4) 40% (8) 
Number of tumors 
 Unique 
 2 to 10 
 >10 
 
43% (19) 
34% (15) 
23% (10) 
 
62% (8) 
15% (2) 
23% (3) 
 
62%(24) 
25%(10) 
12%(5) 
ns 
 
65% (11) 
23% (4) 
12% (2) 
 
59% (13) 
27% (6) 
14% (3) 
Diameter of the main 
lesion: mean ± SD 
(mm) 
81±57 78±48 74±40 ns 77±39 73±42 
Steatosis : 
 No or <10% 
 10-30% 
 30%-60% 
 >60% 
 
7% (3) 
30% (13) 
27% (12) 
36% (16) 
 
77% (10) 
0% 
0% 
23% (3) 
 
44% (17) 
20.5% (8) 
20.5% (8) 
15% (6) 
<10
-4
 
 
47% (8) 
23.5% (4) 
23.5% (4) 
6% (1) 
 
41% (9) 
18%(4) 
18% (4) 
23% (5) 
Microscopic 
hemorrhage 
45% (20) 69% (9) 66% (26) ns 65% (11) 68% (15) 
Dystrophic vessels 23% (10) 38% (5) 46% (18) ns 59% (10) 36% (8) 
Fibrosis 36% (16) 62% (8) 36% (14) ns 29% (5) 42% (9) 
Inflammatory 
infiltrate 
5% (2) 23% (3) 
44% (17) 
<10
-4
 100% (17) 0 
Ductular reaction 9% (4) 0% 18% (7) ns 29% (5) 9% (2) 
Cytological 
abnormalities 
2% (1) 69% (9) 31% (12) <10
-6
 53% (9) 14% (3) 
Pseudo-glandular 
formation 
20% (9) 69% (9) 5% (2) <10
-5
 6% (1) 5% (1) 
Pathological non-
tumor liver (including 
steatosis) 
16% (7) 54% (7) 58% (22) 10
-4
 59% (10) 57% (12) 
Final diagnosis: 
 HA 
 HCC 
 HA with HCC 
 TFNH 
 HA/HCC** 
 HA/TFNH** 
 HA/FNH** 
 
84% (37) 
0 
2% (1) 
0 
5% (2) 
0 
9% (4) 
0 
 
54% (7) 
8% (1) 
23% (3) 
0 
15% (2) 
0 
0 
0 
 
63% (24) 
0 
3% (1) 
8% (3) 
5% (2) 
16% (6) 
5% (2) 
3% (1) 
0.001 
 
50% (8) 
0 
0 
18% (3) 
0 
31% (5) 
0 
6%(1) 
 
73% (16) 
0 
5% (1) 
0 
9% (2) 
5% (1) 
9% (2) 
0 
22 
 Unclassified 
( ): number of cases; HA: hepatocellular adenoma; HCC: hepatocellular carcinoma; FNH: focal 
nodular hyperplasia; TFNH: telangiectatic focal nodular hyperplasia. *P value obtained by 
comparing the three groups HNF1 mutated, ß-catenin activated and non-mutated cases. 
**borderline lesion  
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Table 3: ß-catenin mutations identified in tumors. 
N°ID Nucleotide change Amino acid change 
372 101G>A G34E 
376 98C>G S33Y 
452 IVS2+147_IVS3+62del A5_A80del 
469 100G>A G34R 
517 133T>C S45P 
700 134C>T S45F 
361 7_378del T3_A126del 
477 13_241del A5_A80del 
534 55_425del,insGGT K19_Y142del,insV 
543 60_446del A20_L149del 
505 104A>T K335I 
678 IVS2-49_426del A5_Y142del 
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Figure 1: spectrum of HNF1 mutations. Each bar indicates a point mutation leading to a 
frameshift or a stop codon (upper panel) or to an amino acid substitution (lower panel). In-frame 
deletion and mutations in splicing sites are indicated by a triangle and a circle, respectively. 
Somatic mutations are in black whereas germline mutations are in red. 
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Figure 2: main characteristic morphological features in adenomas. a: typical aspect of a HNF1 
mutated adenoma with marked steatosis, no cytological abnormalities and no inflammatory 
infiltrate (adenomatosis in a 42 year old female patient). b: a ß-catenin activated adenoma 
presenting pseudo-glandular formation (white arrow) and some cytological abnormalities with 
hyperchromatic nuclei (black arrow) in a 14 year old male patient (androgen therapy). c: an 
adenoma without HNF1 nor ß-catenin mutations presenting focal inflammatory infiltrate (white 
arrow) and some cytological abnormalities with hyperchromatic nuclei (black arrow) in a 53 year 
old male patient. d: an adenoma without HNF1 nor ß-catenin mutations and without any 
morphological particularities: no steatosis, no cytological abnormalities and no inflammatory 
infiltrate in a 27 year old female patient. 
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Figure 3: Activation of the ß-catenin pathway in hepatocellular adenomas mRNA expression of 
ß-catenin target genes glutamine synthetase (GS) and GPR49 in tumors. Mean level of expression 
are represented by an horizontal line. Quantitative RT-PCR analysis was performed in samples 
with a good-quality RNA, i.e. 71% of all samples (3 samples with a ß-catenin mutations had no 
qualified RNA). 
s 
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Figure 4: Schematic representation of hepatocellular adenoma classification. Frequencies of 
adenoma associated with HCC or of borderline lesion between adenoma and HCC (Ad-HCC) are 
indicated at the right for each group of tumors. 
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